Gary E. Marais, MB, ChB; Kerry K. Larson, MD
Lovastatin is a new lipid-lowering drug that has shown great promise in the treatment of patients with hypercholesterolemia (1, 2). It is the first available agent in a new class of drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which catalyzes the rate-limiting step in cholesterol synthesis (3). Lovastatin is well tolerated and few severe adverse effects have been reported (4). Myopathy, defined as muscle pain or weakness associated with markedly elevated creatine kinase levels, has a reported incidence of 0.5% (4). Rhabdomyolysis has been reported in 30% of patients when the drug is used concomitantly with immunosuppressive drugs
Learn more about subscription options.
Register Now for a free account.
Marais GE, Larson KK. Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy. Ann Intern Med. 1990;112:228-230. doi: 10.7326/0003-4819-112-3-228
Download citation file:
Published: Ann Intern Med. 1990;112(3):228-230.
Acute Kidney Injury, Cardiology, Coronary Risk Factors, Dyslipidemia, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only